Fumarate disarms CD8+ T cells against cancer
Cell Metabolism · 2023-06 · 35 (6) · 907-909
DOI: 10.1016/j.cmet.2023.05.005 ↗Kurz gefasst
Kommentar in der Zeitschrift Cell Metabolism, 2023-06. Verfasst von Luigi Nezi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Oncology, Istituto Europeo di Oncologia IRCCS, Milano, Italy. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Monzino, Associazione Italiana per la Ricerca sul Cancro, Worldwide Cancer Research.
Abstract (Originalsprache)
The composition of nutrients in the tumor microenvironment is a key determinant of anti-tumor CD8+ T cell response. In this issue of Cell Metabolism, Jiang and colleagues unveil that tumor-derived fumarate dampens TCR signaling in CD8+ T cells, resulting in defective activation, loss of effector functions, and associated failure of tumor control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Experimental Oncology, Istituto Europeo di Oncologia IRCCS, Milano, Italy.
- Department of Experimental Oncology, Istituto Europeo di Oncologia IRCCS, Milano, Italy. Electronic address: teresa.manzo@ieo.it.
Förderung
- Fondazione Istituto Europeo di Oncologia e Centro Cardiologico Monzino
- Associazione Italiana per la Ricerca sul Cancro
- Worldwide Cancer Research
Zitieren
APA
Nezi, L., & Manzo, T. (2023). Fumarate disarms CD8+ T cells against cancer. Cell Metabolism, 35(6), 907-909. https://doi.org/10.1016/j.cmet.2023.05.005
Vancouver
Nezi L, Manzo T. Fumarate disarms CD8+ T cells against cancer. Cell Metabolism. 2023;35(6):907-909. doi:10.1016/j.cmet.2023.05.005
BibTeX
@article{Nezi2023,
author = {Nezi, Luigi and Manzo, Teresa},
title = {Fumarate disarms CD8+ T cells against cancer},
journal = {Cell Metabolism},
year = {2023},
volume = {35},
number = {6},
pages = {907--909},
doi = {10.1016/j.cmet.2023.05.005}
}
EUVIMED